Dr. Shashi Gujar
Inflammation, Infection & Immunity, Cancer
Immunotherapies represent the most promising modern-age modalities for the treatment of cancers. These immunotherapies promote anti-cancer immunity which not only eliminates existing cancer cells, but also maintains an active surveillance against future cancer relapse.
Dr. Gujar discovered that oncolytic viruses, known for their cancer-killing properties, additionally re-educate the immune system to recognize, attack, and eliminate cancer cells. Indeed, such awakening of immune system is believed to be the key to achieve long-term cancer-free health.
Using the next generation OMICs platforms in the context of oncolytic viruses, Dr. Gujar aims to develop innovative and clinically desired immunotherapies for the prevention or treatment of cancers.
The current focus of this research program encompasses the multi-disciplinary collaborative research in the fields of oncolytic viruses, applied immunomics, cancer biology, and cell metabolism. His research is tremendously benefited by the infrastructure acquired through Dalhousie Medical Research Foundation’s Molly Appeal initiatives.